Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
Chlorhexidine 0.02% treatment for refractory blepharoconjunctivitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Greenbaum Eran, Nemet Arie, Segev Fani, Friehmann Asaf
Аннотация
PURPOSE: To report the efficacy and safety of twice daily 0.02% Chlorhexidine in treating chronic refractory blepharoconjunctivitis.
METHODS: A case series of 10 patients with symptomatic, chronic, and resistant-to-treatment bilateral blepharoconjunctivitis were referred to our clinic. Conjunctival swab cultures were obtained, anterior segment photographs were taken, and all patients began treatment with 0.02% chlorhexidine administered twice daily. Clinical signs and symptoms were monitored over the follow-up period.
RESULTS: Of ten patients (20 eyes, mean age was 67.6 +/- 19.05 years), 6/10 had positive cultures of a resistant strain of Staphylococcus aureus or epidermidis previously treated with topical antibiotic drops. All patients showed complete resolution of conjunctival hyperemia and reported substantial improvement of symptoms after 2 weeks of treatment. At 1-month follow-up, the patients reported complete resolution of symptoms. Best corrected visual acuity (BCVA) before and after treatment differences were not statistically significant.
CONCLUSION: Twice-daily application of 0.02% chlorhexidine appears to be a safe and effective treatment for patients with chronic, treatment-resistant blepharoconjunctivitis, offering significant symptomatic relief and clinical improvement.
METHODS: A case series of 10 patients with symptomatic, chronic, and resistant-to-treatment bilateral blepharoconjunctivitis were referred to our clinic. Conjunctival swab cultures were obtained, anterior segment photographs were taken, and all patients began treatment with 0.02% chlorhexidine administered twice daily. Clinical signs and symptoms were monitored over the follow-up period.
RESULTS: Of ten patients (20 eyes, mean age was 67.6 +/- 19.05 years), 6/10 had positive cultures of a resistant strain of Staphylococcus aureus or epidermidis previously treated with topical antibiotic drops. All patients showed complete resolution of conjunctival hyperemia and reported substantial improvement of symptoms after 2 weeks of treatment. At 1-month follow-up, the patients reported complete resolution of symptoms. Best corrected visual acuity (BCVA) before and after treatment differences were not statistically significant.
CONCLUSION: Twice-daily application of 0.02% chlorhexidine appears to be a safe and effective treatment for patients with chronic, treatment-resistant blepharoconjunctivitis, offering significant symptomatic relief and clinical improvement.